OncoMatch/Clinical Trials/NCT07151391
The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue)
Is NCT07151391 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Guarana for neuroendocrine tumors.
Treatment: Guarana — The purpose of this clinical trial is to learn if the drug guarana improves symptoms of fatigue in patients with neuroendocrine tumors and gynecologic cancers
Check if I qualifyExtracted eligibility criteria
Cancer type
Neuroendocrine Tumor
Disease stage
Required: Stage III, IV, I, II
unresected locally advanced or metastatic well differentiated neuroendocrine tumors; early-stage (I or II) ovarian/fallopian-tube cancer; endometrial cancer which is low risk, low-intermediate risk in surveillance, or high-intermediate risk receiving brachytherapy
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: cytotoxic chemotherapy
Receiving treatment with Cytotoxic Chemotherapy, Radiation Therapy, PRRT or TKIs within 6 weeks prior to the first dose of study treatment
Cannot have received: radiation therapy
Receiving treatment with Cytotoxic Chemotherapy, Radiation Therapy, PRRT or TKIs within 6 weeks prior to the first dose of study treatment
Cannot have received: PRRT
Receiving treatment with Cytotoxic Chemotherapy, Radiation Therapy, PRRT or TKIs within 6 weeks prior to the first dose of study treatment
Cannot have received: tyrosine kinase inhibitor
Receiving treatment with Cytotoxic Chemotherapy, Radiation Therapy, PRRT or TKIs within 6 weeks prior to the first dose of study treatment
Lab requirements
Blood counts
Hemoglobin ≥ 9 g/dL
Kidney function
Estimated creatinine clearance ≥ 30 mL/min by Cockcroft-Gault formula
Liver function
Total Bilirubin ≤ 1.5x institutional ULN or ≤3 x ULN with documented liver involvement and/or Gilbert's disease; AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN; Subjects with liver metastases will be allowed to enroll with AST and ALT levels ≤ 5 x ULN.
Adequate organ function as defined as: Hematologic: Hemoglobin ≥ 9 g/dL; Hepatic: Total Bilirubin ≤ 1.5x institutional ULN or ≤3 x ULN with documented liver involvement and/or Gilbert's disease; AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN; Subjects with liver metastases will be allowed to enroll with AST and ALT levels ≤ 5 x ULN. Renal: Estimated creatinine clearance ≥ 30 mL/min by Cockcroft-Gault formula
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Huntsman Cancer Institute at University of Utah · Salt Lake City, Utah
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify